A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Magic Ink.
- Who it may be relevant to
- Registry conditions: Ductal Carcinoma in Situ, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer. Basic parameters: from 18 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Phase I/II Study of Disappearing Markers for Daily Radiation Treatment Delivery
Overview
The goal of this clinical trial is to learn if tattoos applied with Magic Ink is as safe as commercially available standard tattoo ink for the purpose of radiation in women with breast cancer undergoing radiation treatment. The main questions are: * Is the Magic Ink as safe as standard tattoo ink * Does Magic Ink continue to function and remain visible for radiation therapists during the treatment Participants will be consented and given a skin assessment. Once enrolled participants will be administered the Magic Ink tattoo instead of the standard tattoo ink in preparation for their radiation treatment. Participants will also complete a survey regarding body image. Skin assessment will occur again after the first week of radiation and at 3 months later. Throughout the radiation therapy the medical physicist will complete surveys about ease of set-up of the equipment.
Interventions
- Other Magic Ink
A novel ink that is only visible when exposed to Ultraviolet light and can be hidden using white light will be inserted into the dermis to tattoo a radiation guidance tattoo into the skin of the participant
Primary outcome measures
- Safety of Magic Ink [Time frame: 3 months after completion of Radiation Therapy]
Secondary outcome measures (2)
- Efficacy of Magic Ink [Time frame: 3 months after the completion of Radiation Therapy]
- Body Image Score [Time frame: 3 months after the completion of Radiation Therapy]
Eligibility criteria
Inclusion criteria
- Participant must have histologically or cytologically confirmed stage 0 ductal carcinoma in situ (DCIS), I, II or III breast cancer and be planning to undergo radiation therapy (RT) after surgery
- Participants must be 18 years of age or older
- Participant must be able to understand a written informed consent document and be willing to sign it
- Participant must be assigned female at birth
- Participant must have a Karnofsky performance score of greater than or equal to 70%
- Women of child bearing potential must agree to avoid becoming pregnant through defined periods during the course of RT and must meet one of the following:
- Surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy
- Post-menopausal, defined as no menses for at least 12 months prior to the screening visit without alternative medical causation
- Agree to practice true abstinence from sexual intercourse
- Not in a sexual relationship in which the may become pregnant (i.e., same-sex relationship)
- If they are childbearing potential, agree to use at least one highly effective and at least one additional method of contraception.
- For the first six participants only: Participant must have a Fitzpatrick Skin Tone Scale of 5 or 6
Exclusion criteria
- Participants who have received prior radiation treatment to the affected breast.
- Participants with a history of allergic reaction or hypersensitivity attributed to any tattoo ink
- Participants with active chronic skin diseases such as psoriasis. Participants with inactive or controlled skin diseases are eligible for this study
- Participants that are pregnant or breastfeeding. If a participant wishes to participate in this study, breastfeeding should be discontinued
- Participants with a BMI greater than 44.5 as calculated within six months prior to the starting of the study. If there are multiple BMI measurements available in the chart, the most recent will be used to determine eligibility.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
United States · 1 center
- Karmanos Cancer Institute — Detroit
Identifiers
NCT: NCT07095114 · 2025-034